Singapore-Based Global Schools Foundation Announces Strategic Partnership With Vikaasa Schools
SINGAPORE, May 26, 2023 – (ACN Newswire) – Singapore-based Global Schools Foundation (GSF) has announced…
Month: May 2023
Autonomous Mobile Robots by Synergy Dynamics (HK) Ltd Triumph in Warehouse Trials Across China
HONG KONG, May 26, 2023 – (ACN Newswire) – The successful testing period conducted by…
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Cutera, Inc. (CUTR) on Behalf of Investors
BENSALEM, Pa.–(BUSINESS WIRE)–Law Offices of Howard G. Smith announces an investigation on behalf of Cutera,…
Redfin Reports Mortgage Rates Surge Past 7.1% For First Time Since November; Some Buyers Back Off While Others Lower Budget
Monthly housing payments hit a new record high this week as mortgage rates jumped, pricing…
Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2023 Annual Meeting
NEW YORK–(BUSINESS WIRE)–Flatiron Health today announced that the company and its collaborators will present a…
Vahanna Tech Edge Acquisition I Corp. Announces Additional Contribution to Trust Account to Extend Deadline to Consummate Business Combination
NEW YORK–(BUSINESS WIRE)–Vahanna Tech Edge Acquisition I Corp. (NASDAQ: VHNAU, VHNA, VHNAW) (“Vahanna” or the…
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) —…
HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) —…
BioSyent Declares Second Quarter 2023 Dividend
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
BioSyent Declares Second Quarter 2023 Dividend
MISSISSAUGA, Ontario, May 25, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of…
Zentalis Announces Presentation of Positive Phase 1b Data Demonstrating Durable Responses and Favorable Safety Profile of Azenosertib in Combination with Chemotherapy at the 2023 ASCO Annual Meeting
Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of…
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR)…
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Preliminary signs of antitumor activity noted in 36% of patients, with two partial responses (PR)…
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40…
Shattuck Labs to Present Complete Dose-Escalation Data from Phase 1A Monotherapy Clinical Trial of SL-172154 in Platinum-Resistant Ovarian Cancer (PROC) at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
– SL-172154 demonstrated favorable safety and tolerability profile across doses, with maximal CD47 and CD40…
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
Media Release COPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab–bysp in combination with…
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
Media Release COPENHAGEN, Denmark; May 25, 2023 Oral presentations will highlight epcoritamab–bysp in combination with…
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
– Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using…
SpringWorks Therapeutics Announces Presentation of Additional Data from Phase 3 DeFi Trial of Nirogacestat in Adults with Desmoid Tumors at the 2023 ASCO Annual Meeting
– Nirogacestat Treatment Demonstrated Rapid, Sustained and Consistent Reductions in Pain Compared to Placebo Using…